Interestingly, hypercholesterolemia associated with nephrotic syndrome can be ameliorated by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a posttranscriptional regulator of the LDL receptor. The gene discussed is PCSK9; the disease is nephrotic syndrome.